These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29336315)

  • 21. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
    Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
    Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
    Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
    Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
    Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
    Wilmott JS; Menzies AM; Haydu LE; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA; Long GV
    Br J Cancer; 2013 Mar; 108(4):924-31. PubMed ID: 23403819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Ferrucci PF; Gandini S; Battaglia A; Alfieri S; Di Giacomo AM; Giannarelli D; Cappellini GC; De Galitiis F; Marchetti P; Amato G; Lazzeri A; Pala L; Cocorocchio E; Martinoli C
    Br J Cancer; 2015 Jun; 112(12):1904-10. PubMed ID: 26010413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
    Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
    Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming metastatic melanoma with BRAF inhibitors.
    Hong S; Hong S; Han SB
    Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
    Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
    J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
    [No Abstract]   [Full Text] [Related]  

  • 40. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
    Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
    PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.